Literature DB >> 1327095

Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye.

T Matsuo1, M S Cynader.   

Abstract

Prostaglandin F2 alpha reduces intraocular pressure possibly by increasing uveoscleral outflow. To further understand the mechanism of its action binding sites for prostaglandin F2 alpha and, for comparison, prostaglandin E2 were localised in sections of human cadaveric eyes using an in vitro ligand-binding technique and autoradiography. Specific binding sites for both prostaglandin F2 alpha and E2 were co-localised at a high level in the areas of the ciliary muscles and iris sphincter muscles, and at a lower level in the iris epithelium and the retina. The results suggest that prostaglandin F2 alpha and also prostaglandin E2, could modulate uveoscleral outflow by binding to their receptors located on the ciliary muscles and inducing their relaxation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327095      PMCID: PMC504229          DOI: 10.1136/bjo.76.4.210

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  32 in total

Review 1.  Transport of prostaglandins across the blood-brain and blood-aqueous barriers and the physiological significance of these absorptive transport processes.

Authors:  L Z Bito; M C Wallenstein
Journal:  Exp Eye Res       Date:  1977       Impact factor: 3.467

2.  Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha.

Authors:  E Lütjen-Drecoll; E Tamm
Journal:  Exp Eye Res       Date:  1988-11       Impact factor: 3.467

Review 3.  Species differences in the responses of the eye to irritation and trauma: a hypothesis of divergence in ocular defense mechanisms, and the choice of experimental animals for eye research.

Authors:  L Z Bito
Journal:  Exp Eye Res       Date:  1984-12       Impact factor: 3.467

4.  Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey.

Authors:  S F Nilsson; M Samuelsson; A Bill; J Stjernschantz
Journal:  Exp Eye Res       Date:  1989-05       Impact factor: 3.467

5.  Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets in vitro.

Authors:  R M Eglen; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

6.  Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha.

Authors:  K Crawford; P L Kaufman
Journal:  Arch Ophthalmol       Date:  1987-08

7.  The effects of prostaglandin F2 alpha in the human eye.

Authors:  G Giuffrè
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1985       Impact factor: 3.117

8.  Dose-related effects of prostaglandin F2 alpha isopropylester on intraocular pressure, refraction, and pupil diameter in monkeys.

Authors:  K S Crawford; P L Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-03       Impact factor: 4.799

9.  Arachidonic acid metabolism in human trabecular meshwork cells.

Authors:  R N Weinreb; J R Polansky; J A Alvarado; M D Mitchell
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-11       Impact factor: 4.799

10.  Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey.

Authors:  B T Gabelt; P L Kaufman
Journal:  Exp Eye Res       Date:  1989-09       Impact factor: 3.467

View more
  9 in total

1.  Neuroprotective effect of latanoprost on rat retinal ganglion cells.

Authors:  Hideyo Kudo; Toru Nakazawa; Masahiko Shimura; Hidetoshi Takahashi; Nobuo Fuse; Kenji Kashiwagi; Makoto Tamai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

2.  The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1993-02       Impact factor: 4.638

3.  Localisation of thromboxane A2 receptors and the corresponding mRNAs in human eye tissue.

Authors:  Z Chen; S Prasad; M Cynader
Journal:  Br J Ophthalmol       Date:  1994-12       Impact factor: 4.638

4.  Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.

Authors:  T L Davis; N A Sharif
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

5.  Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture.

Authors:  P Cortina; M J Gómez-Lechón; A Navea; J L Menezo; M C Terencio; M Diaz-Llopis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-03       Impact factor: 3.117

Review 6.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Principles of Ocular Pharmacology.

Authors:  Yong Park; Dorette Ellis; Brett Mueller; Dorota Stankowska; Thomas Yorio
Journal:  Handb Exp Pharmacol       Date:  2017

8.  Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes.

Authors:  Afshin Shafiee; Lyle M Bowman; Eddie Hou; Kamran Hosseini
Journal:  Clin Ophthalmol       Date:  2013-07-31

9.  Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications.

Authors:  Jie Shen; Margot L Goodkin; Warren Tong; Mayssa Attar
Journal:  Clin Ophthalmol       Date:  2017-09-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.